I. Scope of treatment: 1. 131I-MIBG for adult malignant pheochromocytoma/paraganglioma; 2. 131I-MIBG for medullary thyroid cancer; 3. 131I for differentiated thyroid cancer; 4. 131I-Metuximab for primary liver cancer; 5. 131I for hyperthyroidism; 6. 90Y/90Sr for conventional chemotherapy in medical oncology; 7. 90Y/90Sr for benign prostatic hyperplasia; 8. BPH; 8. 153Sm, 89Sr for bone metastases; 9. Yunque for endorheumatoid arthritis; 2. 2.Thyroid aspiration 131I test. 3.Radioimmunoassay: TT3 (triiodothyronine), TT4 (thyroxine), FT3 (free triiodothyronine), FT4 (free thyroxine), TSH (thyroid stimulating hormone), TgAb (thyroglobulin antibody), TMAb (thyroid microsomal antibody), Tg (thyroglobulin), AFP (alpha-fetoprotein), CEA ( carcinoembryonic antigen), PSA (prostate-specific antigen), Ca-125 (tumor antigen 125), etc.